Working… Menu

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03422094
Recruitment Status : Terminated (Manufacturer changed focus to cell therapy)
First Posted : February 5, 2018
Last Update Posted : April 23, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 26, 2020
Actual Study Completion Date : December 31, 2020